Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
CTI BioPharma Corp. (GB:0RLB)
LSE:0RLB
CTI BioPharma (0RLB) Share Price & Analysis
0 Followers
0RLB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.65 - €0.65
Previous Close€0.65
Volume0.00
Average Volume (3M)N/A
Market Cap
$1.20B
Enterprise ValueN/A
Total Cash (Recent Filing)$59.01M
Total Debt (Recent Filing)$48.08M
Price to Earnings (P/E)-1.2
BetaN/A
Next Earnings
Aug 03, 2023EPS Estimate
-€0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding131,880,176
10 Day Avg. Volume217
30 Day Avg. VolumeN/A
Standard Deviation0.30
R-Squared0.00093
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)15.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
€8.88Price Target Upside1267.85% Upside
Rating ConsensusHold
Number of Analyst Covering7
CTI BioPharma News
Press ReleasesSobi to Acquire CTI BioPharma
0RLB FAQ
What was CTI BioPharma Corp.’s price range in the past 12 months?
CTI BioPharma Corp. lowest share price was €0.65 and its highest was €0.65 in the past 12 months.
What is CTI BioPharma Corp.’s market cap?
Currently, no data Available
When is CTI BioPharma Corp.’s upcoming earnings report date?
CTI BioPharma Corp.’s upcoming earnings report date is Aug 03, 2023 which is 120 days ago.
How were CTI BioPharma Corp.’s earnings last quarter?
CTI BioPharma Corp. released its earnings results on May 11, 2023. The company reported -€0.091 earnings per share for the quarter, beating the consensus estimate of -€0.104 by €0.013.
Is CTI BioPharma Corp. overvalued?
According to Wall Street analysts CTI BioPharma Corp.’s price is currently Undervalued.
Does CTI BioPharma Corp. pay dividends?
CTI BioPharma Corp. does not currently pay dividends.
What is CTI BioPharma Corp.’s EPS estimate?
CTI BioPharma Corp.’s EPS estimate is -€0.07.
How many shares outstanding does CTI BioPharma Corp. have?
Currently, no data Available
What happened to CTI BioPharma Corp.’s price movement after its last earnings report?
CTI BioPharma Corp. reported an EPS of -€0.091 in its last earnings report, beating expectations of -€0.104. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CTI BioPharma Corp.?
Among the largest hedge funds holding CTI BioPharma Corp.’s share is Perceptive Advisors LLC. It holds CTI BioPharma Corp.’s shares valued at N/A.
---
CTI BioPharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€8.88 (1267.85% Upside)
€8.88 (1267.85% Upside)
Blogger Sentiment
Bullish
GB:0RLB Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CTI BioPharma Corp.
CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
---
CytomX Therapeutics
―
Kala Pharmaceuticals
―
Adamis Pharma
―
G1 Therapeutics
―
CTI BioPharma
―
---